Clinical Trials

131 enrolled

GastrointestinalGenitourinaryThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

NCT03782207 2026-01-08

IMreal

Active not recruiting

2,756 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT06780826 2025-01-17

A Study on the Efficacy of Atezolizumab Combined with Chemotherapy

Recruiting

1,430 enrolled

Small Cell Lung Carcinoma

NCT04920981 2024-11-07

CLINATEZO

518 enrolled

Small Cell Lung Carcinoma

NCT05418660 2023-09-18

I-STOP

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03559647 2023-09-01

The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy

358 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05797493 2023-04-04

PICASSO

Recruiting

100 enrolled

Small Cell Lung Carcinoma

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

DermatologicGenitourinaryThoracic

1,800 enrolled

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03232593 2022-08-24

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

BreastGastrointestinalGenitourinaryThoracic

1,758 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03790397 2022-06-03

OSIREX

169 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04465942 2021-08-23

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

300 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04136470 2020-08-10

BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics

130 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT04145232 2020-08-10

AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient's Response to Immunotherapies.

30 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03228368 2017-07-24

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

10 enrolled